variations relate to the differing prognoses, pain levels, and degrees of body image disruption associated with each tumour type, as well as specific tumour-related neuropsychiatric effects and treatment-related neuropsychiatric side effects. 3 Estimates of the prevalence of major depression in cancer patients greatly exceed the 2% reported for the general population. 8 However, 73% of these depressed cancer patients do not receive effective psychiatric treatment, and only 5% see a mental health professional.
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Symptoms of anxiety in patients with cancer more often coexist with clinical depression than present as anxiety alone, and treatment for depression may also resolve anxiety.
Who is most at risk?
Risk factors for depression and anxiety in cancer are poorly characterised. Those identified for depression in cancer include younger age and social deprivation, and (for colorectal and lung cancers) female gender. 8 Unlike in the general population, anxiety disorders in cancer are not associated with age, gender, or socioeconomic status. 2 They are associated with a history of anxiety or trauma, 10 and (for some cancers) with metastatic disease. 11 Patients who exhibit a tendency to blame themselves for their cancer diagnosis are more likely to become depressed than those who consider other contributory factors. 13 Clinical practice also suggests that severity is influenced by factors such as functional limitations and poor social support.
In our experience patients with pre-existing psychiatric disorder require close vigilance after cancer diagnosis, as this may relapse or worsen at any point in the cancer journey.
Examples include pelvic, breast, or rectal examinations re-traumatising patients with posttraumatic stress disorder, relapse of recurrent depressive disorder after mastectomy, and manic or depressive relapse of bipolar affective disorder due to essential treatment with corticosteroids.
Survival after a cancer diagnosis is reduced in people with pre-existing severe mental illness, even when accounting for delayed diagnosis, with mortality risk 90% higher in patients with schizophrenia and 20% higher in patients with prior depression
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What are the underlying causes?
There are two main pathways by which depression and anxiety can arise in patients with cancer: the processes involved in the biopsychosocial model (with interdependent contributions of biological, psychological, and social factors) and the range of specific neuropsychiatric effects of certain cancers and their treatments. Cancer treatment may be an under-recognised yet reversible cause of severe (and sometimes rapid onset) illness.
Biopsychosocial causes
Depression and anxiety in cancer most commonly arise from a patient's psychological reactions to diagnosis, treatment, relapse, end of life care, or survivorship. 14 Losses inherent to treatment (such as hair, sexual function, or organs), expectations regarding survival, and the effects on work and social roles can lead to protracted periods of psychological stress. fig 1) . Anxiety in patients with cancer is understood to reach pathological levels where it significantly impairs usual functioning, and is disproportionate to the level of threat. 
Direct neuropsychiatric effects of cancers or treatment
No precise estimates are available for the proportion of depression or anxiety cases attributable to the direct biological effects of specific tumours or cancer treatments. Limited tumour-specific studies confirm that they represent a clinically significant minority.
Site-specific cancers
Several specific tumour types give rise to depression or anxiety (see infographic), most commonly tumours of the pancreas (severe cytokine-mediated depression) and lung (depressive and anxiety symptoms due to endocrine paraneoplastic syndromes).
About 70% of patients with pancreatic cancer experience depression, 50% have anxiety, and 30% experience both, with depression arising months before the cancer diagnosis and also late in the disease. 15 Levels of the cytokine interleukin-6, released by the tumour, are directly proportional to the severity of the depression.
Among patients with small cell lung cancer (SCLC), 15% will develop the syndrome of inappropriate antidiuretic hormone secretion (SIADH), of whom a large proportion would be expected to experience low mood driven by hyponatraemia.
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A third example is depression arising from malignant hypercalcaemia, which affects approximately 1% of UK cancer patients. 19 This is driven by ectopic parathormone-related peptide production in non-small cell lung cancer (NSCLC), myeloma, sarcoma, breast, renal, gynaecological, and head & neck cancers, but also arises from bone metastases in a range of tumours.
Cancer treatments
Corticosteroids can cause hypomania (often with psychotic features) at high doses and depression with longer-term low doses. Less well recognised by clinicians are the adverse neuropsychiatric effects of some conventional chemotherapeutic agents, hormone deprivation treatment, newer immunotherapies and targeted agents, 20 radiotherapy, and cancer surgery (see infographic and supplementary boxes 1-4 on bmj.com).
For example, in trials of androgen deprivation therapy for prostate cancer, men report statistically significantly higher rates of depression and anxiety throughout nine months of treatment than at baseline. After pelvic irradiation for gynaecological cancer, 14% of patients acquire vitamin B12 deficiency due to disrupted gut absorption, and here again depression is a common presenting complaint.
Bilateral oophorectomy in premenopausal women, whether as cancer prophylaxis or treatment, is associated with a long term increased risk of depressive disorder and of anxiety symptoms.
At which points in the cancer journey are patients affected by anxiety and depression?
Pre-diagnosis
Depression and anxiety may be the first sign of cancer for tumours exerting direct biologically-mediated effects on mood (see infographic). 18 This highlights the importance of excluding organic differentials when assessing all new psychiatric presentations. The incidence of cancer diagnosis in the first month after a first psychiatric presentation for anxiety is over triple that for the rest of the population, and particularly high in people over 65 years old. 18 Among patients aged over 50 years presenting to psychiatric services for the first time with depression, an estimated one in 54 will be diagnosed with cancer within a year; predominantly those cancers with neuropsychiatric effects.
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Diagnosis and treatment
The estimated prevalence of depression is highest during the acute phase of cancer treatment. 22 Feelings of hopelessness as part of the syndrome of depression may influence refusal of cancer treatment. Up to 50% of women with breast cancer have a diagnosis of depression, anxiety, or both in the year after diagnosis, falling to 15% over five years.
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Severe depression can sometimes present acutely during conventional chemotherapy, particularly for taxane-based chemotherapies, and post-chemotherapy depression may persist for up to 18 months.
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Discharge
For some patients, an intense schedule of clinic, imaging, and treatment appointments delays their psychological adjustment to the cancer diagnosis until after treatment, which can Item: BMJ-UK; Article ID: pita038917; Article Type: Clinical review; TOC Heading: Practice; DOI: 10.1136/bmj.k1415
Page 6 of 11 be understood as a protective form of denial. 25 Once the milestone of surgery or chemotherapy has passed, this may be the point at which a patient starts to consider the significance of a potentially life-threatening event and adjusts to long-term physical changes, at which point depression and/or anxiety may emerge (see patient's perspective box).
Discharge from cancer services can represent a sudden cessation of regular support for some patients, and the perceived abandonment can increase levels of anxiety to diagnostic thresholds.
End of life
Perhaps contrary to expectations, the estimated prevalences of depression (all types combined), and anxiety during end-of-life care (25% and 10% respectively) do not differ from those in non-palliative care settings. Stepped care: Standard treatment guidelines apply to depression and anxiety in patients with cancer, but the following points highlight special considerations in cancer. These deliver evidence-based therapies to individuals or groups, but they may not be available outside urban centres. Improving Access to Psychological Therapies (IAPT), the English programme for treating depression and anxiety, may be more accessible and also offers group or individual therapies, but services may lack specialist training in the complexities of working with cancer. Such expertise includes addressing adherence to treatment, complex illness beliefs, challenging side effects (including psychosexual), physical disfigurement, and end-of-life issues. How patients were involved in the creation of this article We interviewed a range of our patients with cancer to find out what they felt were the important aspects to address in an article about psychiatric problems in cancer, and they mentioned the importance of highlighting that the nature of patients' distress changes as they transition through diagnosis, treatment, and post-treatment (for example when waiting for test results or living in fear of recurrence), and of being aware "that we may not be able to voice what's really going on for us, and (practitioners) may need to delve a little bit deeper to really help us".
Integrated Mental and Physical Cancer
We invited a patient representative to write a personal perspective on her experiences of depression in the context of cancer diagnosis and treatment and to review our article for its coverage of key points. She felt it was important to highlight how common mental health problems were both during and after cancer treatment, and the need for specialist psychological input.
